Increased proportion of the squamous cell carcinoma component is associated with worse survival in resected gastric adenosquamous carcinoma

Li, Hongshuai; Chen, Ye; Zhang, Mingyi; Cheng, Ke; Zhou, Yuwen; Liu, Jiyan

doi:10.1097/md.0000000000021980

Cited by 2 publications

(3 citation statements)

References 33 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Studies have determined the correlation among treatment outcomes, pathological features, and clinical parameters. [5][6][7] Determination of the proportion of the SCC component in tumors can have a prognostic value. However, optimal treatment modalities and predictive biomarkers remain unclear.…”

Section: Introductionmentioning

confidence: 99%

Immunoprofile of adenosquamous carcinoma in gastric cancer

Lai

Teng

et al. 2023

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Background: Gastric adenosquamous carcinoma (GASC) is a rare subtype of gastric cancer. Research on GASC treatment is limited, and its outcome is usually poor. We investigated the clinical features, immunoprofile of GASC, and determined the optimal treatment modality for these patients. Methods: Patients with GASC from Taipei Veterans General Hospital were retrospectively reviewed. Clinical features and treatment outcomes were evaluated. Adequate samples were examined for surrogate biomarkers for immunotherapy by IHC staining. Results: Total 14 (0.35%) GASC patients were found among 4034 gastric cancer patients. The median tumor size was 6.8 cm in 10 patients with stage III GASC, and all these patients underwent radical gastrectomy followed by adjuvant therapy. The median progression-free survival (PFS) and overall survival (OS) were 6.0 and 11.5 months, respectively. Two patients with stage IV GASC received frontline immunotherapy. Their median PFS and OS were 9.0 and 12.5 months. In immunoprofiling, 25.0% (n = 3), 75.0% (n = 9), and 33.3% (n = 4) of the samples had deficient mismatch repair (dMMR) protein, combined positive score (CPS) of ≥1, and CPS of ≥10, respectively. The univariate analysis revealed that programmed death-ligand 1 ≥5% (HR: 0.12; 95% CI: 0.01-0.97; p = 0.047) was significant associated with superior OS. One stage IV patient with CPS ≥10 and dMMR proteins received nivolumab monotherapy as frontline treatment that resulted 14-month PFS. Conclusion: Patients with GASC are more likely to yield positive results for CPS and dMMR. Biomarkers should be examined, and immunotherapy can be considered as frontline systemic treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunoprofile of adenosquamous carcinoma in gastric cancer

Lai

Teng

et al. 2023

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

show abstract

“…4,5 Poor differentiation is a common tendency, 4-6 and the presence of a squamous component appears to contribute to a poor prognosis. 7 In the study titled "Immunoprofile of adenosquamous carcinoma in gastric cancer," Wu et al 8 investigated the clinical features, treatment outcomes, and immunoprofile of GASC to determine the optimal treatment modality for these patients. The authors retrospectively reviewed patients with GASC from a single institute and analyzed their clinical data and tumor samples.…”

mentioning

confidence: 99%

“…4,5 Poor differentiation is a common tendency, 4–6 and the presence of a squamous component appears to contribute to a poor prognosis. 7…”

mentioning

confidence: 99%

Understanding gastric adenosquamous cell carcinoma: Insights from immunoprofiling

Liu

2023

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Gastric adenosquamous cell carcinoma (GASC), like other adenosquamous cell carcinomas of the digestive system, is a rare histological subtype with aggressive tumor behavior. 1 Recent literature has focused on characterizing the clinicopathological features and distinct clinical outcomes compared to its adenocarcinoma counterpart. While some studies have reported the lower third of the stomach as the most common site for adenosquamous cell carcinoma, 2,3 larger registry database studies have reported a higher frequency in the gastric cardia (upper third). 4,5 Poor differentiation is a common tendency, 4-6 and the presence of a squamous component appears to contribute to a poor prognosis. 7 In the study titled "Immunoprofile of adenosquamous carcinoma in gastric cancer," Wu et al 8 investigated the clinical features, treatment outcomes, and immunoprofile of GASC to determine the optimal treatment modality for these patients. The authors retrospectively reviewed patients with GASC from a single institute and analyzed their clinical data and tumor samples. The study found that the median tumor size in stage III GASC patients was 6.8 cm, and all of these patients underwent radical gastrectomy followed by adjuvant therapy. The median progression-free survival (PFS) and overall survival (OS) for stage III GASC patients were 6.0 and 11.5 months, respectively. Two patients with stage IV GASC received frontline immunotherapy, with a median PFS and OS of 9.0 and 12.5 months, respectively. Immunoprofiling of the GASC samples revealed that 25% of the samples had deficient mismatch repair (dMMR) protein, 75% had a combined positive score (CPS) of ≥1, and 33.3% had a CPS of ≥10. The study also found that programmed death-ligand 1 expression of ≥5% was significantly associated with superior OS. One stage IV patient with CPS ≥10 and dMMR proteins received nivolumab monotherapy as frontline treatment, resulting in a PFS of 14 months. The study suggests that patients with GASC are more likely to exhibit positive results for CPS and dMMR. It highlights the importance of examining biomarkers

show abstract

Increased proportion of the squamous cell carcinoma component is associated with worse survival in resected gastric adenosquamous carcinoma

Abstract: Supplemental Digital Content is available in the text

Cited by 2 publications

References 33 publications

Immunoprofile of adenosquamous carcinoma in gastric cancer

Immunoprofile of adenosquamous carcinoma in gastric cancer

Understanding gastric adenosquamous cell carcinoma: Insights from immunoprofiling

Contact Info

Product

Resources

About